PALI - Why Palisade Bio Stock Is Soaring Today | Benzinga
Palisade Bio, Inc. (NASDAQ:PALI) shares are trading higher Tuesday after the company announced the completion of its analysis evaluating ex-vivo bioactivation of PALI-2108.
The Details:
Palisade Bio said the findings demonstrated PALI-2108 exhibited efficient ex-vivo conversion into its active PDE4 inhibitor form in stool samples from both normal healthy volunteers and patients with ulcerative colitis (UC). The assessment showed PALI-2108 was converted into its active PDE4 inhibitor form at a mean rate of 90.1% with conversion steadily increasing over time.
“The results from this study underscore our confidence in PALI-2108 as a targeted treatment for moderate-to-severe UC,” said Dr. Mitch Jones, CMO at Palisade Bio.
“The successful bioactivation of prodrug PALI-2108 into its active PDE4 inhibitor form at consistently high conversion rates over a 24-hour period in stool samples highlights its promise as ...